Search clinical trials for: time management

Total 23852 results

Eli Lilly and Company

Completed

Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer

Breast Cancer

Argentina, Belgium, Germany, Romania, Spain, United Kingdom
Eli Lilly and Company

Completed

Duloxetine Versus Paroxetine for Major Depression

Major Depressive Disorder

China
Eli Lilly and Company

Completed

Duloxetine Versus Placebo for Fibromyalgia

Fibromyalgia

United States
Eli Lilly and Company

Completed

Growth Hormone Treatment in Short Children Born Small for Gestational Age

Infant, Small for Gestational Age

Germany
Eli Lilly and Company

Completed

Evaluation of Continuous Symptom Treatment of ADHD

Attention Deficit Hyperactivity Disorder

United States
Hadassah Medical Organization

Unknown

Orthodontic Treatment With a Part-Time Wearing Esthetic Removable Appliance

Malocclusion

Israel
Eli Lilly and Company

Completed

Comparison Atomoxetine Hydrochloride and Comparator in Pediatric Outpatients With ADHD

Attention Deficit Hyperactivity Disorder

China, Mexico, Korea, Republic of
Eli Lilly and Company

Completed

Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With Schizophrenia

Schizophrenia

Japan
Eli Lilly and Company

Completed

Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics

Schizophrenia

China
Eli Lilly and Company

Completed

Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy

Attention Deficit Hyperactivity Disorder

United States
Eli Lilly and Company

Completed

Safety Study in Outpatient Japanese Children With ADHD

Attention Deficit Hyperactivity Disorder

Japan
Eli Lilly and Company

Completed

A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD

Attention Deficit Hyperactivity Disorder

Netherlands
Eli Lilly and Company

Completed

Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression

Bipolar Disorder

United States
Eli Lilly and Company

Completed

Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD

Attention Deficit Hyperactivity Disorder

Taiwan
Eli Lilly and Company

Completed

Olanzapine Versus Comparator in the Treatment of Bipolar Disorder

Bipolar Disorder

China
Eli Lilly and Company

Completed

Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia

Schizophrenia

Taiwan
University Hospital, Bordeaux
Ministry of Health, France

Unknown

Comprehensive Management of Diabetic Patients With Renal Impairment : Impact on Blood Pressure and Glycemic Control

Diabetic Nephropathies

France
Eli Lilly and Company

Completed

Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD

Attention Deficit Hyperactivity Disorder

United States
Eli Lilly and Company

Completed

Combination Therapy in Patients With Depression

Depressive Symptoms

United States
Eli Lilly and Company

Completed

Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder

Bipolar Disorder

United States
Eli Lilly and Company

Completed

Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial

Postmenopausal Osteoporosis

Germany, Spain, Greece, Mexico, Israel, Czech Republic
Eli Lilly and Company

Completed

Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia

Schizophrenia

United States, Russian Federation, Croatia
Eli Lilly and Company

Completed

Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia

Schizophrenia

United States, Russian Federation
Eli Lilly and Company

Completed

Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Attention Deficit Disorder With Hyperactivity

Russian Federation
Eli Lilly and Company

Completed

Evaluation of the Effects of Duloxetine on Norepinephrine

Major Depressive Disorder

United States
Eli Lilly and Company

Completed

A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia

Schizophrenia

Japan
Eli Lilly and Company

Completed

Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder

Attention Deficit Hyperactivity Disorder | Comorbid Social Anxiety Disorder

United States, Puerto Rico
Eli Lilly and Company

Completed

Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS) (LEAPS)

Major Depressive Disorder

United States
Eli Lilly and Company

Completed

Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Eli Lilly and Company

Completed

Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents

Breast Neoplasms

France, Germany, Italy, Netherlands, Spain, United Kingdom
Eli Lilly and Company

Completed

A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment

Breast Cancer | Ovarian Cancer | Endometrial Cancer

United States
Santa Casa de Passos

Terminated

Intraoperative Fluid Management Based on Arterial Pulse Pressure Variation During High-Risk Surgery

Surgery

Brazil
Eli Lilly and Company

Completed

Effects of Teriparatide in Postmenopausal Women With Osteoporosis

Postmenopausal Osteoporosis

United States
Eli Lilly and Company

Completed

Duloxetine vs. Active Comparator in the Treatment of Patients With Depression

Depression

France
Eli Lilly and Company
Boehringer Ingelheim

Completed

Duloxetine vs Placebo in the Treatment of General Anxiety

Anxiety

United States
Eli Lilly and Company

Completed

Study of Duloxetine in Elderly Patients With Major Depressive Disorder

Depression | Cognition

United States
Eli Lilly and Company

Completed

Urge Incontinence Bladder Overactivity Study

Urinary Incontinence

United States, Australia, Canada
Eli Lilly and Company

Completed

Efficacy and Safety Stress Urinary Incontinence Study

Urinary Incontinence, Stress

Taiwan
Eli Lilly and Company

Completed

Duloxetine Stress Urinary Incontinence Efficacy and Safety Study

Urinary Incontinence, Stress

Korea, Republic of
Eli Lilly and Company

Completed

Duloxetine vs. Active Comparator for the Treatment of Depression

Depression

Canada
Eli Lilly and Company

Completed

A Study for the Treatment of Painful Diabetic Neuropathy

Diabetic Neuropathy, Painful

United States
Eli Lilly and Company
Boehringer Ingelheim

Completed

A Study of Duloxetine in the Treatment of Fibromyalgia

Fibromyalgia

Argentina, Australia, Brazil, Canada, Mexico, Poland, Taiwan
Eli Lilly and Company

Completed

Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy

Ovarian Neoplasms | Primary Peritoneal Cancer

Spain, Germany, Belgium, United Kingdom
Eli Lilly and Company

Completed

A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer

Superficial Bladder Cancer

Israel
Eli Lilly and Company

Completed

Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen

Vasomotor Symptoms | Endometrial Safety

United States
Eli Lilly and Company

Completed

Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis

Osteoporosis, Postmenopausal

Canada, United States
Eli Lilly and Company

Completed

A Study in People With Mild Hypertension

Mild Hypertension

Sweden
China Medical University Hospital

Unknown

Diabetes Quality Improvement Program on Diabetes Case Management Program 2001 (DQIP-DCMP)

Diabetes Mellitus

Taiwan
The Christie NHS Foundation Trust

Terminated

Effect of Pegvisomant on GH/IGF-I Relationship in GHD

Severe Adult Growth Hormone Deficiency

United Kingdom
Eli Lilly and Company

Completed

Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.

Non-Small-Cell Lung Carcinoma

United States

Search clinical trials for: time management

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations